Mesoblast: Back Pain And Heart Failure Remain Option Value, Not Base Case
Source: SeekingAlpha
2025-10-07 14:57:04 ET
Introduction
Mesoblast’s stock ( MESO ) is up 70% since my rating upgrade from Sell to Hold in July 2025....
Read the full article on Seeking Alpha
For further details see:
Mesoblast: Back Pain And Heart Failure Remain Option Value, Not Base Case
Mesoblast Ltd Ord
NASDAQ: MEOBF
MEOBF Trading
0.0% G/L:
$1.55 Last:
2,000 Volume:
$1.55 Open:
MEOBF Latest News
March 11, 2026 07:21:39 pm
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
MEOBF Stock Data
$2,165,966,075
573,072,937
N/A
91
N/A
Biotechnology & Life Sciences
Healthcare
AU
Melbourne
